The stock has a 36-month beta value of 1.38. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMAB is 76.81M, and at present, short sellers hold a 1.22% of that float. On March 05, 2025, the average trading volume of IMAB was 411.27K shares.
IMAB) stock’s latest price update
I-Mab ADR (NASDAQ: IMAB)’s stock price has dropped by -2.96 in relation to previous closing price of 0.90. Nevertheless, the company has seen a loss of -7.96% in its stock price over the last five trading days. globenewswire.com reported 2025-02-18 that ROCKVILLE, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) — I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision immune-oncology agents for the treatment of cancer, today announced that members of I-Mab’s management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday and Wednesday, March 11-12, 2025.
IMAB’s Market Performance
I-Mab ADR (IMAB) has seen a -7.96% fall in stock performance for the week, with a -8.07% decline in the past month and a -6.21% plunge in the past quarter. The volatility ratio for the week is 6.02%, and the volatility levels for the past 30 days are at 5.83% for IMAB. The simple moving average for the past 20 days is -7.33% for IMAB’s stock, with a -28.96% simple moving average for the past 200 days.
Analysts’ Opinion of IMAB
Many brokerage firms have already submitted their reports for IMAB stocks, with Siebert Williams Shank repeating the rating for IMAB by listing it as a “Buy.” The predicted price for IMAB in the upcoming period, according to Siebert Williams Shank is $96 based on the research report published on December 09, 2021 of the previous year 2021.
Needham gave a rating of “Buy” to IMAB, setting the target price at $75 in the report published on March 15th of the previous year.
IMAB Trading at -10.80% from the 50-Day Moving Average
After a stumble in the market that brought IMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.28% of loss for the given period.
Volatility was left at 5.83%, however, over the last 30 days, the volatility rate increased by 6.02%, as shares sank -9.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.34% lower at present.
During the last 5 trading sessions, IMAB fell by -8.35%, which changed the moving average for the period of 200-days by -52.16% in comparison to the 20-day moving average, which settled at $0.9431. In addition, I-Mab ADR saw 2.86% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMAB starting from KANNAN RAJ, who proposed sale 50,000 shares at the price of $1.39 back on Jul 26 ’24. After this action, KANNAN RAJ now owns shares of I-Mab ADR, valued at $69,500 using the latest closing price.
Stock Fundamentals for IMAB
Current profitability levels for the company are sitting at:
- -100.18 for the present operating margin
- 1.0 for the gross margin
The net margin for I-Mab ADR stands at -80.35. The total capital return value is set at -1.81. Equity return is now at value -39.60, with -30.80 for asset returns.
Currently, EBITDA for the company is -1.21 billion with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 37.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.50.
Conclusion
To sum up, I-Mab ADR (IMAB) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
